VANCOUVER, British Columbia, Feb. 22, 2019 --
InvestorsHub NewsWire -- ICC International
Cannabis Corp. (CSE:WRLD.U)(8K51.F)(WLDCF)
("ICC" or “International
Cannabis”or the “Company”) is
pleased to provide the following updates pertaining to the
Company’s medical cannabis (“THC”) and cannabidiol (“CBD”) asset
portfolio.
Over the past three quarters, International
Cannabis has deployed an aggressive acquisition strategy, amassing
a robust portfolio of vertically integrated cannabis assets and
industry partnerships. Upon pending closing of the Company’s
proposed Letter of Intent (“LOI”) with Wayland Group, the Company
will boast the following operations, partnerships, licenses and
asset exposure:
- German medical
Cannabis import license, three-year supply contract to import
35,000 kg of medical cannabis, 165 hectares of CBD cultivation
operations, annual production of over 2,400 kilograms of CBD
isolate, German indoor medical THC cultivation licence
application;
- 820,000 square foot
Ebersbach facility located just outside of Dresden, Germany:
- Replacement cost of 110 million euros;
- Of the many applicants to apply for German medical THC
cultivation licences, only two have a completed facility, and of
those that do, the largest is 14,000 square feet or 1.7 per cent
the size of the Ebersbach facility
- Danish medical THC
cultivation and manufacturing license:
- Stage A will include a 49,600 square foot cultivation unit, as
well as a production and processing structure. All structures
scheduled for construction have been designed to comply with EU-GMP
standards;
- 100 acre land package;
- Engagement of leading greenhouse engineering and manufacturing
firm, Azrom;
- No medical cannabis production cap or quotas;
- Access to skilled agricultural and manufacturing labour
force;
- Local plant breeding and genetics expertise; and
- Well-financed health care system
- Distribution or
supply agreements with over 39,000 corporate and independent
pharmacies, augmented by various value-added services, including
strategic procurement, warehousing, product registrations and
regulatory representations;
- 155 metric tonnes of
extraction-ready hemp inventories, resulting in near-immediate
access to superior CBD concentrates;
- Exclusive supply
agreement for the delivery of 400 metric tonnes of certified
organic hemp from a licensed Croatian producer;
- First European
Guaranteed Issue Medical Cannabis Coverage:
- First of its kind transformative coverage for cannabinoid
therapeutic treatment via the BuyWell Care platform;
- Online medical cannabis coverages utilizing a proprietary
pricing methodology;
- Over 500 million potential consumers;
- Over 1.6 million health care practitioners; and,
- Annual healthcare expenditures of $1.79 trillion in
2018.
- CBD Health and
Wellness e-commerce marketplace;
- Catalogue of
430 proprietary genetics, seeds and strains;
- Polish hemp
processing and extraction license:
- Operations are currently producing CBD distillate, isolate,
bulk oils, and tinctures;
- Access to over 850 acres of premium hemp crops, estimated to
yield up to 6,800 tons of material for CBD extraction;
- Existing extraction and manufacturing facility; and,
- Existing sales agreements across various EU member
countries
- 60,000 square foot
Swiss cannabis cultivation facility, proprietary genetics portfolio
available for export, THC distillate import capabilities and
pending material revenues from Haxxon AG operations;
- Leading candidacy
for one of seven medical cannabis licences to be issued by the
Italian government, as well as an pending ownership interest in a
joint venture to produce cannabis products;
- Licenses for medical
cannabis cultivation, manufacturing, distribution, transport,
research and import/export in the Kingdom of Lesotho;
- Rich soils, ideal climate, skilled agricultural work force,
low-cost labour and access to key infrastructure;
- 300 days of sunshine annually;
- First African nation to legalize medical cannabis; and,
- Ideal climate for low-cost greenhouse cannabis
production
- Supply agreement to
provide cannabis products to over 2,800 independent and corporate
pharmacies across South Africa;
- Maltese licence to
manufacture finished-dose medical cannabis;
- Portuguese hemp
cultivation and processing license:
- Notable importer of EU licensed hemp seeds;
- Access to 400 acres of fertile agricultural land located in the
Castelo Branco region of Portugal; and,
- Progressing towards a full spectrum cannabis license;
- Colombian licences
for THC/CBD production, extraction and export, as well as pending
access to a European Union good-manufacturing-practice-certified
API facility for cannabis distillate processing;
- 90-per-cent working
interest in a Greek industrial hemp license and medical cannabis
pre-approval support letter:
- 16 acre land package situated within the Greek prefecture of
Imathia;
- Exclusive agreement
with an existing Macedonian licensed facility, permiting the
cultivation, manufacturing, extraction and export of medical
cannabis:
- 3,000,000 square feet of cultivation space built under glass;
one of the largest impending European cannabis facilities;
- 30 hectare land parcel in Valandovo, Macedonia
- Licenses in Bulgaria
for the production, manufacturing and export of both hemp and
medical cannabis;
- Leading candidacy
for a United Kingdom-based medical cannabis import licence;
- Leading candidacy
for an Australian late-stage medical cannabis;
- Leading candidacy
for the first Argentine federal medical cannabis licence and
existing supply agreements for CBD products;
International Cannabis is uniquely positioned
to capture significant market share, as the European THC and CBD
industries continue to mature. We have tactically secured
cornerstone assets Denmark and Germany- jurisdictions armed with
broad insurance coverage, affording the Company the ability to
realize substantially higher margins, while insulating our
operations from margin compression”.
The Company’s acquisition strategy, including
its proposed transaction with Wayland Group, further reinforce the
ICC’s corporate mandate of:
- Optimizing its
upstream, downstream, and distribution capabilities;
- Integrating
operational best practices into its medical plant production,
extraction, active pharmaceutical ingredient isolation and finished
dose manufacturing operations;
- Executing upon its
first-mover advantage in rapidly maturing jurisdictions;
- Providing a robust
suite superior quality products; and,
- Championing the
European consumer’s THC/CBD retail experience.
Mr. Beukman, continued: “Our extraction-ready hemp stockpiles,
deep-seated understanding of regional business practices and vast
Pan-European distribution footprint safeguards our ability to
maximize opportunities in Europe’s emerging CBD and THC markets.
The Company continues to place particular emphasis on furthering
its operations in the European and LATAM regions and will look to
execute an assertive acquisition strategy focused on Asia Pacific
theatre over the upcoming quarter”.
ABOUT INTERNATIONAL
CANNABIS
ICC International, through its subsidiaries,
has operating assets and is developing a world-class platform for
cultivation, extraction, formulation and distribution across the
globe in the United Kingdom, Denmark, Poland, Switzerland, Germany,
Macedonia, Bulgaria, Serbia, Croatia, Greece, Italy, Portugal,
Malta, Colombia, Argentina, Australia, South Africa and
Lesotho.
ON BEHALF OF THE ICC INTERNATIONAL
CANNABIS CORP BOARD OF DIRECTORS
Eugene Beukman
CEO, Director
+1 (604) 687-2038
info@intlcannabiscorp.com
Learn more about ICC by visiting our website at: https://intlcannabiscorp.com/
Stay up to date with everything happening at ICC by following or
liking us on:
Facebook - https://www.facebook.com/ICCWRLD/
Twitter - https://twitter.com/ICC_WRLD
LinkedIn - https://www.linkedin.com/company/icc-wrld/
THE CSE HAS NOT REVIEWED AND DOES NOT ACCEPT
RESPONSIBILITY FOR THE ACCURACY OR ADEQUACY OF THIS
RELEASE.
Notice Regarding Forward Looking
Information:
This news release contains certain
"forward-looking information" within the meaning of applicable
Canadian securities law. Forward-looking information is frequently
characterized by words such as "plan", "continue", "expect",
"project", "intend", "believe", "anticipate", "estimate", "may",
"will", "potential", "proposed" and other similar words, or
information that certain events or conditions "may" or "will"
occur. This information is only a prediction. Various assumptions
were used in drawing the conclusions or making the projections
contained in the forward-looking information throughout this news
release. Forward-looking information includes, but is not limited
to: political changes in Canada and internationally, future
legislative and regulatory developments involving cannabis in
Canada and internationally, the Company’s ability to secure
distribution channels in international jurisdictions, competition
and other risks affecting the Company in particular and the
cannabis industry generally.
The forward-looking information contained in
this release is expressly qualified by the foregoing cautionary
statements and is made as of the date of this release. Except as
may be required by applicable securities laws, the Company does not
undertake any obligation to publicly update or revise any forward-
looking information to reflect events or circumstances after the
date of this release or to reflect the occurrence of unanticipated
events, whether as a result of new information, future events or
results, or otherwise.